Programme SOM0044 for Parkinson’s Disease
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
Regeneron reports two-year diabetic retinopathy data of Eylea
Patients treated with Eylea experienced a reduction of at least 75% in the risk of the vision-threatening events. Credit: Laitr Keiows.
Learn more
Hover over the logos to learn more about the companies who made this project possible.
Close
-
CSM, a Clinigen company
CSM, a Clinigen company, focuses on clinical trial supplies and...
About
CSM, a Clinigen company, focuses on clinical trial supplies and biological sample management services.
FollowMake an Enquiry
-
Experic
Experic is a contract manufacturing organization (CMO) and pharmaceutical supply...
About
Experic is a contract manufacturing organization (CMO) and pharmaceutical supply services company, which supports all stages of a product’s lifecycle from clinical to commercial scale.
FollowMake an Enquiry
-
SOM Biotech
SOM Biotech is an Artificial Intelligence AI drug discovery and...
About
SOM Biotech is an Artificial Intelligence AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology.
FollowMake an Enquiry